Emerging Infections Program Change Request February 2014

Amy McMillen, MPH Centers for Disease Control and Prevention National Center for Emerging and Zoonotic Infectious Diseases Office of the Director 1600 Clifton Rd Atlanta GA 30333 404-639-1045 <u>auh1@cdc.gov</u>

Background

The National Center for National Center for Emerging and Zoonotic Infectious Diseases (NCEZID) of the Centers for Disease Control and Prevention (CDC) is requesting approval of changes to four data collection forms that have previously been approved under OMB no. 0920-0978; expiration date 8/31/2016.

These forms are used to conduct surveillance to determine the incidence and epidemiologic characteristics of invasive disease due to *Haemophilus influenzae*, *Neisseria meningitidis*, group A *Streptococcus*, group B *Streptococcus*, *Streptococcus pneumoniae*, methicillin-resistant *Staphylococcus aureus*, *Legionella spp.*, specific foodborne diseases that is captured within FoodNet and Influenza (specifically for the All Age Influenza Hospitalization Surveillance (Flu Hosp) project).

The forms for which approval for changes are being sought include:

- 1. 2014 ABCs Case Report Form (Attachment 1)
- 2. 2014 ABCs Invasive Methicillin-resistant *Staphylococcus aureus* Case Report Form (Attachment 2)
- 3. 2014 ABCs Neonatal Infection Expanded Tracking Form (Attachment 3)
- 4. 2014 ABCs Legionellosis Case Report Form (Attachment 4)
- 5. 2014 FoodNet Variable list (Attachment 5)
- 2013-14 FluSurv-NET Influenza Surveillance Project Case Report Form (Attachment 6)
- 7. 2013-14 FluSurv-NET Influenza Surveillance Project Vaccination History Telephone Survey (Attachment 7)
- 8. 2013-14 FluSurv-NET Influenza Surveillance Project Vaccination History Telephone Survey (Spanish) (Attachment 8)
- 9. 2013-14 FluSurv-NET Influenza Surveillance Project Consent Form (Attachment 9)
- 10. 2013-14 FluSurv-NET Influenza Surveillance Project Consent Form (Spanish) (Attachment 10)

Description of Changes

Minor changes are being requested for the 2014 ABCs Case Report Form, the 2014 ABCs Invasive Methicillin-resistant *Staphylococcus aureus* Case Report Form, the 2014 Neonatal Infection Expanded Tracking Form and the 2014 ABCs Legionellosis Case Report Form in order to streamline and enhance disease surveillance for the pathogens under surveillance.

Minor changes are being requested for the 2014 FoodNet Variable list in order to improve disease surveillance under FoodNet surveillance.

Minor changes are being requested for the 2013-14 FluSurv-NET Influenza Surveillance Project Case Report Form, 2013-14 FluSurv-NET Influenza Surveillance Project Vaccination History Telephone Survey, 2013-14 FluSurv-NET Influenza Surveillance Project Vaccination History Telephone Survey (Spanish), 2013-14 FluSurv-NET Influenza Surveillance Project Consent Form, 2013-14 FluSurv-NET Influenza Surveillance Project Consent Form (Spanish) to improve surveillance of hospitalized cases affected by influenza. The changes from the previously approved forms are minimal and the addition of forms translated to Spanish will not result in a change to previously estimated burden hours, as per communication with surveillance officers (form respondents).

Detailed Description of Changes

- A. 2014 ABCs Case Report Form changes include:
 - 1. Question 27: Underlying conditions or prior illnesses
 - Two checkboxes, 'Chronic Renal Insufficiency' and 'Renal Failure/Dialysis' have been removed.
 - Two checkboxes, 'Chronic Kidney Disease' and 'Current Chronic Dialysis' were added to distinguish between persons with underlying renal conditions that do or do not require dialysis.
 - 2. Question 30, 'Is patient currently attending college?' has been moved to the left to be better grouped with other questions specific to cases of *N*. *meningitidis*.

B. 2014 ABCs Invasive Methicillin-resistant *Staphylococcus aureus* Case Report Form changes include:

- 1. The order of the questions have been reordered to improve logic flow and shading added to indicate core variables
- 2. Question 18: Supplemental Pneumonia Questions, has been removed.
- 3. Hospital discharge date was moved to question on patient outcome.
- 4. New question added, 'If yes, (to culture collected > 3 days after hospital admission) was the case selected for full CRF based on sampling frame 1:10?'
- 5. Modified question on BMI- added text' (do not calculate, only if available in the MR).'
- 6. Underlying conditions
 - Changed 'AIDS or CD4 count < 200' to 'AIDS'
 - Changed 'Chronic Renal Insufficiency' to 'Chronic Kidney Disease'
 - Added checkbox for 'Chronic Cognitive Deficit', to more closely match the Charlson co-morbidity index.
- 7. Changed title of question from 'Classification Healthcare-associated and community-associated' to 'Prior healthcare exposure Healthcare associated and community-associated'.

C. 2014 ABCs Neonatal Infection Expanded Tracking Form changes include:

1. Question 9: new question 9c. added; 'Were *any* ICD-10 codes reported in the discharge diagnosis of the infant's chart? This was added to capture ICD-10 codes.

2. Question 9: new question 9d. added ; 'If yes, were any of the following ICD-10 codes reported in the discharge diagnosis of the chart?' This was added to capture ICD-10 codes.

3. Question 19: will no longer indent 'If delivery was by C-section...'. This will be left aligned to match the rest of the form's questions.

4. Question 26: An unknown checkbox was added for unknown dates of prenatal care visits, to indicate that the question was reviewed and data was missing.

D. 2014 ABCs Legionellosis Case Report Form changes include:

1. Question 22: Discharge diagnosis; we are adding ICD-10 codes to the appropriate variables capturing ICD-9 codes, where matching ICD-10 codes exist.

- 2. Question 23: Underlying conditions or prior illnesses
 - Two checkboxes, 'Chronic Renal Insufficiency' and 'Renal Failure/Dialysis' have been removed.
 - Two checkboxes, 'Chronic Kidney Disease' and 'Current Chronic Dialysis' were added to distinguish between persons with underlying renal conditions that do or do not require dialysis.
- E. 2014 FoodNet Variable list changes include:

1. Variable 2: Expanded the list of responses for 'AgClinicTestType' to reflect new tests that are now being used in clinical labs.

2. Variables 80 & 81: Added two new variables ('DXO157' and 'DXO157TestType') related to culture-independent testing for STEC.

3. Variables 10-57: Added new variables to capture case exposure information to be used for attribution estimates. These variables were developed by a working group consisting of CDC and state health department sites over a two-year period. Variables were pilot-tested in 4 sites for a three-month period for Salmonella and Campylobacter cases. These variables are already being captured by state health departments on their state forms.

F. 2013-14 FluSurv-NET Influenza Surveillance Project Case Report Form

1. To better characterize the types of FluSurv-NET cases, a question has been added to differentiate between patients admitted to the hospital versus those who are kept under observation for 24 hours or more.

2. To better classify patient's residence before hospitalization, we have replaced the long term care facility information open text fields and replaced them with checkboxes of the most common responses for residence prior to hospitalization.

3. Question regarding whether or not patient worked in the healthcare industry has been removed.

4. To better capture information regarding symptoms at the time of admission, question E2 "Reason for current admission" has been rephrased to "Acute conditions at admission".

5. To better understand high risk behaviors associated with influenza hospitalizations, questions regarding previous and current smoking status and previous and current alcohol abuse have been added

6. A question has been added for the patient's total number of ICU admissions during current hospitalization to better capture the history of the

hospitalization since a patient may have more than one admission to state forsmthe ICU.

7. The antiviral treatment section of the case report form has been reformatted to better capture treatment information, including method of administration and multiple series of medications

8. The options for terms abstracted from radiographic reports were modified slightly to harmonize with other surveillance tools already in use in similar catchment areas.

9. The options available for discharge locations have been modified to make the form consistent with the information encountered by the surveillance officers when abstracting data from medical charts.

10. Vaccination history for mothers of patients < 6 months of age will no longer be collected.

11. The section on vaccination status was simplified. We will capture vaccination status according to each data source used at the surveillance area and vaccine type will no longer be collected.

12. Pneumococcal vaccination status will no longer be collected.

G. 2013-14 FluSurv-NET Influenza Surveillance Project Vaccination History Telephone Survey

1. To reflect changes made in the 2013-14 FluSurv-NET Influenza Surveillance Project Case Report Form, the 2013-14 FluSurv-NET Influenza Surveillance Project Vaccination History Telephone Survey was simplified.

- Vaccination history for mothers of patients < 6 months of age will no longer be collected.
- The vaccine type will no longer be collected.
- Pneumococcal vaccination status will no longer be collected.
- H. 2013-14 FluSurv-NET Influenza Surveillance Project Vaccination History Telephone Survey (Spanish)

1. To better obtain surveillance information of Spanish-speaking individuals, the 2013-14 FluSurv-NET Influenza Surveillance Project Vaccination History Telephone Survey has been translated into Spanish.

I. 2013-14 FluSurv-NET Influenza Surveillance Project Consent Form

1. Instructions on where to proceed after the interviewee consents to the continuation of the interview has been changed to better reflect this season's instructions.

J. 2013-14 FluSurv-NET Influenza Surveillance Project Consent Form (Spanish)
 1.To better obtain surveillance information of Spanish-speaking individuals, the
 2013-14 FluSurv-NET Influenza Surveillance Project Consent Form has been
 translated into Spanish.

Cross walk of 2014 form changes

A. 2014 ABCs Case Report Form

Question on 2013 form	Question on 2014 form
27. Underlying conditions	27. Underlying conditions
1 Chronic Renal Insufficiency	1 🗆 Chronic Kidney Disease
1 🗆 Renal Failure/Dialysis	1 Current Chronic Dialysis

B. 2014 ABCs Invasive Methicillin-resistant Staphylococcus aureus Case Report Form

Question on 2013 form	Question on 2014 form
18. Supplemental Pneumonia	Removed
Questions. Please complete if the	
patient was determined to have	
pneumonia per question 15a	
(Timeframe of interest: within +/- 3	
calendar days of initial culture)	
9. Was the patient hospitalized, at the	18. Patient Outcome
time of, or in the 30 calendar days, after	9 □ Unknown
initial culture?	$1 \square$ Survived
$1 \square$ Yes $2 \square$ No $9 \square$ Unknown	Date of discharge: MM/DD/YYYY
If yes, date of admission:	$2 \square \text{Died}$
MM/DD/YYYY	Date of death: MM/DD/YYYY
Date of discharge: MM/DD/YYYY	
17. Classification – Healthcare-	11. Was culture collected >3 calendar
associated and community-associated:	days after hospital admission?
(Check all that apply)	1 □ Yes (HO-MRSA case)
	$2 \square$ No (Complete CRF, CA-MRSA or
$1 \square$ Culture collected >3 calendar days	HACO-MRSA case)
after hospital admission.	If was a use the same calested for full
	If yes, was the case selected for full
	CRF based on sampling frame 1:10?
	$1 \square$ Yes (Complete CRF) $2 \square$ No (STOP data abstraction)
8f. BMI: □ unknown	12e. BMI: (do not calculate,
	only if available in MR)
16. Underlying conditions	20. Underlying conditions
$1 \square$ AIDS or CD4 count <200	$1 \square AIDS$
$1 \square$ Chronic Renal Insufficiency	$1 \square$ Chronic Renal Disease
	$1 \square$ Chronic Cognitive Deficit
17. Classification – Healthcare-	21. Prior Healthcare Exposure -
associated and community-associated:	Healthcare-associated and community-
(Check all that apply)	associated: (Check all that apply)

Question on 2013 form	Question on 2014 form
N/A	9c. Were <i>any</i> ICD-10 codes reported in
	the discharge diagnosis of the infant's
	chart?
N/A	9d. IF YES, were any of the following
	ICD-10 codes reported in the discharge
	diagnosis of the chart? (Check all that
	apply)
	$1 \square B36$: Bacterial sepsis of newborn
	$1 \square$ B36.0: Sepsis of newborn due to
	streptococcus, group B
	$1 \square$ B36.1: Sepsis of newborn to other
	and unspecified streptococci
	$1 \square$ B95.1: Streptococcus, group b as
	the cause of diseases classified
	elsewhere
	$1 \square A40.1$: Sepsis due to streptococcus,
	group B
	$1 \square A40.9$: Streptococcus sepsis,
	unspecified
	$1 \square B95.5$: Unspecified streptococcus as the cause of diseases classified
	elsewhere
26 Diagon record the following: the	1 G00.2: Streptococcal meningitis
26. Please record the following: the total number of prenatal visits AND the	26. Please record the following: the total number of prenatal visits AND the
first and last visit dates to the prenatal	first and last visit dates to the prenatal
provider as recorded in the labor and	provider as recorded in the labor and
delivery chart.	delivery chart.
denvery chart.	
No. of visits:	No. of visits:
First visit: MM/DD/YYYY	First visit: MM/DD/YYYY
Last visit: MM/DD/YYYY	Last visit: MM/DD/YYYY
	$1 \square$ Unknown

C. 2014 ABCs Neonatal Infection Expanded Tracking Form

D. 2014 ABCs Legionellosis Case Report Form

Question on 2013 form	Question on 2014 form
22. Discharge diagnosis	22. Discharge diagnosis
$1 \Box 482.84$ (Legionnaire's disease)	1 🗆 482.84/A48.1 (Legionnaire's
$1 \Box 482$ (Other bacterial pneumonia)	disease)
$1 \Box 482.3$ (Pneumonia due to other	$1 \Box 482$ (Other bacterial pneumonia)
specified bacteria)	$1 \Box 482.3$ (Pneumonia due to other

1 🗆 482.83 (Other gram-negative	specified bacteria)
bacteria)	1 🗆 482.83/J15.6 (Other gram-negative
$1 \Box 482.89$ (Pneumonia due to other	bacteria)
specified bacteria)	1 🗆 482.89/J15.8 (Pneumonia due to
1 🗆 482.9 (Bacterial pneumonia	other specified bacteria)
unspecified)	1 🗆 482.9/J15.9 (Bacterial pneumonia
$1 \Box 483$ (Pneumonia due to other	unspecified)
specified organism)	$1 \Box 483$ (Pneumonia due to other
$1 \Box 483.8$ (Pneumonia due to other	specified organism)
specified organism)	$1 \Box 483.8$ /J16.8 (Pneumonia due to
$1 \Box 484$ (Pneumonia in infectious	other specified organism)
diseases classified elsewhere)	$1 \Box 484$ (Pneumonia in infectious
$1 \Box 484.8$ (Pneumonia in infectious	diseases classified elsewhere)
diseases classified elsewhere)	$1 \Box 484.8/J17$ (Pneumonia in infectious
$1 \Box 485$ (Bronchopneumonia, organism	diseases classified elsewhere)
unspecified)	$1 \Box 485/J18.0$ (Bronchopneumonia,
$1 \Box 486$ (Pneumonia, organism	organism unspecified)
unspecified)	1 □ 486/J18.9 (Pneumonia, organism
$1 \square$ None of these listed	unspecified)
$1 \square$ No ICD-9 codes in chart	$1 \square$ None of these listed
	$1 \square$ No ICD codes in chart
23. Underlying conditions	23. Underlying conditions
$1 \square$ Chronic Renal Insufficiency	$1 \square$ Chronic Kidney Disease
1 □ Renal Failure/Dialysis	$1 \square$ Current Chronic Dialysis

E. 2014 FoodNet Variable list

Variable list 2012	Variable list 2014
2. AgClinicTestType	2. AgClinicTestType
$1 \square$ Immunocard STAT! EHEC (Meridian);	1 □ Alere Shiga Toxin Quik Chek
$1 \square$ Duopath Verotoxins (Merck);	1 \Box Immunocard STAT! EHEC (Meridian);
$1 \square$ Premier EHEC (Meridian);	1 \Box Duopath Verotoxins (Merck);
$1 \square$ ProSpecT STEC (Remel);	1 □ Premier EHEC (Meridian);
$1 \square$ VTEC Screen (Denka Seiken);	$1 \square$ ProSpecT STEC (Remel);
1 🗆 ImmunoCard STAT! Crypto/Giardia	1 □ VTEC Screen (Denka Seiken);
(Meridian);	1 🗆 Alere Giardia/Crypto Quik Chek
$1 \square$ XPect Cryptosporidium (Remel);	1 🗆 ImmunoCard STAT! Crypto/Giardia
$1 \square$ XPect Crypto/Giardia (Remel);	(Meridian);
1 🗆 ColorPAC Crypto/Giardia (Becton	$1 \square$ XPect Cryptosporidium (Remel);
Dickinson);	1 □ XPect Crypto/Giardia (Remel);
$1 \square$ ProSpecT Cryptosporidium (Remel);	1 🗆 ColorPAC Crypto/Giardia (Becton
$1 \square$ ProSpecT Crypto/Giardia (Remel);	Dickinson);
$1 \square$ Wampole EIA Cryptosporidium;	1 ProSpecT Cryptosporidium (Remel);
$1 \square$ TechLab EIA Cryptosporidium;	1 □ ProSpecT Crypto/Giardia (Remel);

$1 \square$ Crypto CELISA (Cellabs);	$1 \square$ Wampole EIA Cryptosporidium;
1 🗆 Para-TECT Crypto Antigen 96	$1 \square$ TechLab EIA Cryptosporidium;
(Medical Chemical Corporation);	$1 \square$ Crypto CELISA (Cellabs);
1 🗆 Triage parasite panel (BioSite)	1 Para-TECT Crypto Antigen 96 (Medical
ProSpecT Campylobacter assay (Remel);	Chemical Corporation);
$1 \square PREMIER^{TM} CAMPY assay$	1 □ Triage parasite panel (BioSite)
(Meridian);	ProSpecT Campylobacter assay (Remel);
1 □ ImmunoCard STAT! CAMPY	$1 \square \text{PREMIER}^{\text{TM}} \text{CAMPY assay (Meridian);}$
(Meridian);	$1 \square$ ImmunoCard STAT! CAMPY (Meridian);
$1 \square$ Xpect Campylobacter assay (Remel);	$1 \square$ Xpect Campylobacter assay (Remel);
$1 \square$ Other;	$1 \square$ Other;
1 🗆 Unknown	1 □ Unknown
N/A	10. CEA_Beef
	11. CEA_Beef_grnd
	12. CEA_Beef_out
	13. CEA_Beef_unckgrnd
	14. CEA_Berries
	15. CEA_Bird
	16. CEA_Cantaloupe
	17. CEA_Cat
	_
	18. CEA_Chicken
	19. CEA_Chx_grnd
	20. CEA_Chx_out
	21. CEA_Dairy
	22. CEA_Dog
	23. CEA_Eggs
	24. CEA_Eggs_out
	25. CEA_Eggs_unck
	26. CEA_Farm_ranch
	27. CEA_Fish
	28. CEA_Fish_unck
	29. CEA Herbs
	30. CEA_Lettuce
	31. CEA_Live_poultry
	32. CEA_Milk_raw
	33. CEA_Odairy_raw
	34. CEA_Ountreat_water
	35. CEA_Pig
	36. CEA_Pocketpet
	37. CEA_Pork
	38. CEA_Raw_cider
	39. CEA_Reptile_amphib
	40. CEA_Ruminants
	41. CEA_Seafd
	42. CEA_Seafd_unck
	43. CEA_Sewer_water
L	

	44. CEA_Sick_contact
	45. CEA_Sick_pet
	46. CEA_Softcheese
	47. CEA_Softcheese_raw
	48. CEA_Spinach
	49. CEA_Sprouts
	50. CEA_Swim_treat
	51. CEA_Swim_untreat
	52. CEA_Tomatoes
	53. CEA_Turkey
	54. CEA_Turkey_grnd
	55. CEA_Turkey_out
	56. CEA_Watermelon
	57. CEA_Well_water
	Responses for all variables listed above (\Box Yes;
	□No; □Unknown)
N/A	80. DXO157
	$1 \square$ Positive;
	$1 \square$ Negative;
	$1 \square$ Not tested
N/A	81. DXO157TestType
	1 ImmunoCard STAT! O157 (Meridian)
	$1 \square$ Diatherix;
	$1 \square$ Luminex;
	$1 \square$ Metametrix;
	$1 \square Other$

F. 2013-14 FluSurv-NET Influenza Surveillance Project Case Report Form

Question on 2011-12 Form	Question on 2013-14 Form
N/A	C2. Admission Type: Hospitalization Observation Only
C12. Was patient a resident of an institutional setting or other chronic care facility prior to hospitalization (e.g., nursing home, prison, long-term care facility)? Yes No Unknown	C13. Where did patient reside at the time of hospitalization? Indicate TYPE of residence. Private residence Rehabilitation facility Group home/Retirement home Assisted living/Residential care Homeless/Shelter Nursing home Unknown Other, specify:
C12a. If yes, indicate TYPE of facility:	Removed
C13. Does patient work in the healthcare industry?	Removed

□ No □ Unknown	
E2.Reason for current admission (Check all that apply): Acute respiratory illness Asthma and/or COPD exacerbation Pneumonia Other respiratory or cardiac conditions Other, neither respiratory nor cardiac conditions Unknown	E2. Acute conditions at admission (Check all that apply): Acute respiratory illness Asthma and/or COPD exacerbation Fever Pneumonia Other respiratory or cardiac conditions Other, neither respiratory nor cardiac conditions Unknown
N/A	E7. Smoker: Current Former No/Unknown
N/A	E8. Alcohol abuse: Current Former No/Unknown
N/A	F1a. Number of ICU Admissions Unknown
I1a. If yes, indicate which antiviral medication(s) were used, or check unknown: Antiviral Medication(s) Unknown	Removed

Question on 2011-12 Form	Question on 2013-14 Form
I1a. If yes, indicate which antiviral medication(s) were	I2a-I5a. Treatment 1-4:
used, or check unknown:	🛛 Oseltamivir (Tamiflu)
Amantadine (Symmetrel)	🗌 Zanamivir (Relenza)
Series 1: [<i>Start Date</i>] [<i>End Date</i>] Series 2:	Amantadine (Symmetrel)
[Start Date] [End Date]	Rimantadine (Flumadine)
Rimantadine (Flumadine)	Other, specify:
Series 1: [Start Date] [End Date] Series 2:	Unknown
[Start Date] [End Date]	
🗌 Zanamivir (Relenza)	
Series 1: [Start Date] [End Date] [Frequency	
and Dose]	
Series 2: [Start Date] [End Date] [Frequency	
and Dose]	
🛾 Oseltamivir (Tamiflu)	
Series 1: [Start Date] [End Date] [Frequency	
<u>and Dose]</u>	
Series 2: [Start Date] [End Date] [Frequency	
<u>and Dose]</u>	
Other, specify:	
Series 1: [Start Date] [End Date] [Frequency]	
and Dose]	
Series 2: [Start Date] [End Date] [Frequency	
and Dose]	

N/A	I2b-I5b. Method of Administration: Oral Intravenous (IV) Inhaled Unknown
N/A	I2c-I5c. Start Date: / I Start Date Unknown
N/A	I2d-I5d. End Date: // [] End Date Unknown
N/A	I2e-I5e. Dose
N/A	I2f-I5f. Frequency:
J2b. For first abnormal chest x-ray, please check all that	J2b. For first abnormal chest x-ray, please check all that
apply:	apply:
Report not available	🗌 Report not available
🛛 Bronchopneumonia/pneumonia	Consolidation
Cannot rule out pneumonia	Interstitial infiltrate
Air space density/opacity	Air space density/opacity
Consolidation	Atelectasis
Interstitial infiltrate	Pleural effusion/empyema
☐ Pleural effusion ☐ Single lobar infiltrate	□ Bronchopneumonia/pneumonia □ Cavitation
☐ Multiple lobar infiltrate (unilateral or bilateral)	Lobar (NOT interstitial) infiltrate
Other, specify:	Cannot rule out pneumonia
	ARDS (acute respiratory distress syndrome)

Question on 2011-12 Form	Question on 2013-14 Form
N/A	J2c. Please specify location for bronchopneumonia/pneumonia/consolidation/lobar infiltrate/air space density/opacity: Single lobar Multiple lobar (unilateral) Multiple lobar (bilateral) Unknown
K3a. If discharged alive, please indicate to where: Home Other hospital Hospice Long-term care facility Other, specify: Unknown	K2a. If discharged alive, please indicate to where: Home Other hospital Hospice/Home hospice Homeless/Shelter Rehabilitation Facility Group home/Retirement home Assisted living/Residential Care Home with Services Nursing home Other, specify: Unknown
M1. Did patient's <u>mother</u> receive the influenza vaccine during fall or winter of the current influenza season? Yes No	Removed

Unknown	
M1a. If yes, specify <u>mother's</u> vaccine type: Injected Vaccine – Trivalent inactivated influenza vaccine (TIV) Nasal Spray – Live attenuated influenza vaccine (LAIV) Vaccine type unknown	Removed
M2b. If yes, specify <u>patient's</u> vaccine type: [] Injected Vaccine – Trivalent inactivated influenza vaccine (TIV) [] Nasal Spray – Live attenuated influenza vaccine (LAIV) [] Vaccine type unknown	Removed
<pre>M2c. If patient ≥ 18 years and received injected vaccine (TIV), please specify type: Regular IM High dose IM Intradermal TIV type unknown</pre>	Removed
M4. Did patient receive any type of pneumococcal vaccine at any age? Yes No Unknown	Removed

Question on 2011-12 Form	Question on 2013-14 Form
M4a. If yes, please provide dosage date information: Dose 1// Dose 2// Dose 3 (Pediatrics Only)// Dose 4 (Pediatrics Only)// Only)// Dose 4 (Pediatrics Only)/	Removed
M4b. If patient ≥ 65 years, was vaccine received within last five years? ☐ Yes ☐ No ☐ Unknown	Removed

G. 2013-14 FluSurv-NET Influenza Surveillance Project Vaccination History Telephone Survey

Question on 2011-12 Form	Question on 2013-14 Form
Patients <6 months old:	Removed
1) Did [you (if speaking to patient's	
mother)/patient's mother] receive the influenza	
vaccine during fall or winter of the current	
influenza season?	
Yes (go to Q1a)	

No (go to Q2)Unknown (go to Q2)	
Patients <6 months old: 1a) If yes, what vaccine type did [you/the patient's mother] receive? Shot [Injected vaccineTrivalent inactivated influenza vaccine (TIV)] Spray [Nasal spray Live- attenuated influenza vaccine (LAIV)] Unknown	Removed
Patients <6 months old: 1b) What type of injected vaccine did [you/patient's mother] receive? ☐ Regular IM ☐ High dose IM ☐ Intradermal ☐ TIV type unknown	Removed
Patients <6 months old: 2) At any time, did [your child/patient's name] receive the pneumonia vaccine [may need to read: pneumococcal, PCV(7), PCV(13), or Prevnar®]?	Removed
Patients <6 months old: 2a) Can you tell me the dates [your child's/patient's name] received the pneumonia vaccine? 1) [MM- DD-YYYY] 2) [MM- DD-YYYY] 3) [MM- DD-YYYY] 4) [MM- DD-YYYY]	Removed
Patients <6 months old: 3) Can you tell me what is [your child's/patient's name] race (check all that apply)?	Removed

 White Black or African American Asian/Pacific Islander American Indian or Alaska Native Multiracial, unspecified Not specified (refused) Are you / they? Hispanic or Latino Non-Hispanic or Latino 	
Children>6 months old and Adults: 1b) Did [you/child's name] receive a shot or was it sprayed into their nose? Shot [Injected vaccineTrivalent inactivated influenza vaccine (TIV)] Spray [Nasal spray Live- attenuated influenza vaccine (LAIV)] Unknown	Removed
Children >6 months old: 3). At any time, did [you/child's name] receive the pneumonia vaccine [may need to read: pneumococcal, PCV(7), PCV(13), or Prevnar®]?	Removed
Adult Patient: 1b) Did [you/child's name] receive a shot or was it sprayed into their nose? Shot [Injected vaccineTrivalent inactivated influenza vaccine (TIV)] Spray [Nasal spray Live- attenuated influenza vaccine (LAIV)] Unknown	Removed
Adult Patient: 1c) What type of injected vaccine did [you/patient's name] receive? Regular IM High dose IM Intradermal TIV type unknown	Removed

Adult Patients:	Removed
2) At any time, did [you/patient's name)	
receive the pneumonia vaccine [may need to	
read: pneumococcal, Pneumovax®]?	
🗌 Yes	
🗌 No	
Unknown	

- H. 2013-14 FluSurv-NET Influenza Surveillance Project Vaccination History Telephone Survey (Spanish)
 - a. To better obtain surveillance information of Spanish-speaking individuals, the 2013-14 FluSurv-NET Influenza Surveillance Project Vaccination History Telephone Survey has been translated into Spanish.

I. 2013-14 FluSurv-NET Influenza Surveillance Project Consent Form

Question on 2011 12 Form	
Question on 2011-12 Form	Question on 2013-14 Form
Hello. My name is from the[state]	Hello. My name is from the[state]
Department of Public Health. May I speak to	Department of Public Health. May I speak to
[patient's name /parent of [child's name]]. We are	[patient's name /parent of [child's name]]. We are
working with the Centers for Disease Control and	working with the Centers for Disease Control and
Prevention and other health departments to learn more	Prevention and other health departments to learn more
about influenza disease or the flu. To do this, we are	about influenza disease or the flu. To do this, we are
talking to people who have been in the hospital with the	talking to people who have been in the hospital with the
flu. We want to look at things that may affect their	flu. We want to look at things that may affect their
illness and whether they were vaccinated against the flu.	illness and whether they were vaccinated against the flu.
Because you/your child [or NAME if speaking with	Because you/your child [or NAME if speaking with
proxy] were in the hospital for the flu beginning on	proxy] were in the hospital for the flu beginning on
[day admitted], I would like to ask you a few	[day admitted], I would like to ask you a few
questions about whether you/your child [or NAME if	questions about whether you/your child [or NAME if
speaking with proxy] received the flu vaccine this	speaking with proxy] received the flu vaccine this
season. This will take about five minutes. Your	season. This will take about five minutes. Your
participation is voluntary and if you choose to refuse it	participation is voluntary and if you choose to refuse it
will not affect any medical care or benefits you receive.	will not affect any medical care or benefits you receive.
All of your responses will be kept confidential as much	All of your responses will be kept confidential as much
as the law allows. You may refuse to answer any	as the law allows. You may refuse to answer any
questions and may stop at any time. This information	questions and may stop at any time. This information
will help [State/Local Health Department] and CDC	will help [State/Local Health Department] and CDC
better describe influenza-associated hospitalizations.	better describe influenza-associated hospitalizations.
Additionally, this information may help us improve	Additionally, this information may help us improve
vaccination recommendations for flu and better protect	vaccination recommendations for flu and better protect
the public's health. There is no other benefit to you for	the public's health. There is no other benefit to you for
answering these questions. There is also no risk to you.	answering these questions. There is also no risk to you.
If you have any questions about the study, you may call	If you have any questions about the study, you may call
[state contact] at the Department of Public Health	[state contact] at the Department of Public Health
at XXX-XXX-XXXX. Do you have any questions	at XXX-XXX-XXXX. Do you have any questions
before I begin?	before I begin?

May I continue with this interview? Yes No If YES, go to Appendix D. If NO: Thank you for your time. Have a good day. 	May I continue with this interview? Yes No If YES, go to Appendix F. If NO: Thank you for your time. Have a good day.
Question on 2011-12 Form	<u>Question on 2013-14 Form</u>
 Hello. My name is from the[state] Department of Public Health. May I speak to [patient's name /parent of [child's name]]. We are working with the Centers for Disease Control and Prevention and other health departments to learn more about influenza disease or the flu. To do this, we are talking to people who have been in the hospital with the flu. We want to look at things that may affect their illness and whether they were vaccinated against the flu. Because you/your child [or NAME if speaking with proxy] were in the hospital for the flu beginning on[day admitted], I would like to ask you a few questions about whether you/your child [or NAME if speaking with proxy] received the flu vaccine this season. This will take about five minutes. Your participation is voluntary and if you choose to refuse it will not affect any medical care or benefits you receive. All of your responses will be kept confidential as much as the law allows. You may refuse to answer any questions and may stop at any time. This information will help [State/Local Health Department] and CDC better describe influenza-associated hospitalizations. Additionally, this information may help us improve vaccination recommendations for flu and better protect the public's health. There is no other benefit to you for answering these questions. There is also no risk to you. If you have any questions about the study, you may call[state contact] at the Department of Public Health at XXX-XXX-XXXX. Do you have any questions before I begin? 	 Hello. My name is from the[state] Department of Public Health. May I speak to [patient's name /parent of [child's name]]. We are working with the Centers for Disease Control and Prevention and other health departments to learn more about influenza disease or the flu. To do this, we are talking to people who have been in the hospital with the flu. We want to look at things that may affect their illness and whether they were vaccinated against the flu. Because you/your child [or NAME if speaking with proxy] were in the hospital for the flu beginning on[day admitted], I would like to ask you a few questions about whether you/your child [or NAME if speaking with proxy] received the flu vaccine this season. This will take about five minutes. Your participation is voluntary and if you choose to refuse it will not affect any medical care or benefits you receive. All of your responses will be kept confidential as much as the law allows. You may refuse to answer any questions and may stop at any time. This information will help [State/Local Health Department] and CDC better describe influenza-associated hospitalizations. Additionally, this information may help us improve vaccination recommendations for flu and better protect the public's health. There is no other benefit to you. If you have any questions about the study, you may call[state contact] at the Department of Public Health at XXX-XXX-XXXX. Do you have any questions before I begin?
□ Yes □ No If YES, go to Appendix D. If NO: Thank you for your time. Have a good day.	□ Yes □ No If YES, go to Appendix F. If NO: Thank you for your time. Have a good day.
IT INC. Thank you for your time. Have a good day.	II INO. IIIdiik you toi youi tille. Have a good day.

- J. 2013-14 FluSurv-NET Influenza Surveillance Project Consent Form (Spanish)
- a. To better obtain surveillance information of Spanish-speaking individuals, the 2013-14 FluSurv-NET Influenza Surveillance Project Consent Form has been translated into Spanish.